Statements (38)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2013 |
| gptkbp:ATCCode |
gptkb:L01XE23
|
| gptkbp:brand |
gptkb:Tafinlar
|
| gptkbp:CASNumber |
1195765-45-7
|
| gptkbp:chemicalFormula |
C23H20F3N5O2
|
| gptkbp:combines |
gptkb:trametinib
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:eliminatedIn |
urine
feces |
| gptkbp:halfLife |
8 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
dabrafenib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
BRAF inhibitor
|
| gptkbp:metabolism |
gptkb:CYP2C8
gptkb:CYP3A4 |
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1173605
gptkb:DB08912 11561899 |
| gptkbp:sideEffect |
gptkb:cutaneous_squamous_cell_carcinoma
fever arthralgia hyperglycemia |
| gptkbp:target |
gptkb:BRAF_V600E_mutation
|
| gptkbp:UNII |
0N5Q73JZ5N
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
gptkb:anaplastic_thyroid_cancer melanoma |
| gptkbp:bfsParent |
gptkb:RAF_kinase
gptkb:BRAF gptkb:BRAF_gene gptkb:Mekinist |
| gptkbp:bfsLayer |
5
|